Journal article
Last but not least: BFL-1 as an emerging target for anti-cancer therapies
G Wang, ST Diepstraten, MJ Herold
Biochemical Society Transactions | Published : 2022
DOI: 10.1042/BST20220153
Open access
Abstract
BFL-1 is an understudied pro-survival BCL-2 protein. The expression of BFL-1 is reported in many cancers, but it is yet to be clarified whether high transcript expression also always correlates with a pro-survival function. However, recent applications of BH3-mimetics for the treatment of blood cancers identified BFL-1 as a potential resistance factor in this type of cancer. Hence, understanding the role of BFL-1 in human cancers and how its up-regulation leads to therapy resistance has become an area of great clinical relevance. In addition, deletion of the murine homologue of BFL-1, called A1, in mice showed only minimal impacts on the well-being of these animals, suggesting drugs targetin..
View full abstractGrants
Awarded by Cass Foundation
Funding Acknowledgements
We thank all our current and past colleagues at WEHI. Our work was supported by grants and fellowships from the Australian National Health and Medical Research Council (NHMRC) (Project Grants 1186575 and 1145728,1143105,1159658 and Fellowship 1156095 to M.J.H.), the Leukaemia and Lymphoma Society of America (LLS SCOR 7015-18 to M.J.H.), the Cancer Council of Victoria (AppID-000012 and Venture Grant to M.J.H.), the Australian Phenomics Network (to M.J.H.), the Victorian Cancer Agency (Early-Career Fellowship 21006 to S.T.D.) and the CASS Foundation (to S.T.D.).